Reacción #2146698

ord-f286747f16134b25b6e7fc31688de88b

Ecuación de reacción

O
water
O=C([O-])[O-].[K+].[K+]
potassium carbonate
Oc1ccc(-c2cn3cc(I)ccc3n2)cc1
2-(4′-hydroxyphenyl)-6-iodoimidazo[1,2-a]pyridine
FCCCBr
1-bromo-3-fluoropropane
FCCCOc1ccc(-c2cn3cc(I)ccc3n2)cc1
2-[4′-(3″-fluoropropoxy)phenyl]-6-iodoimidazo[1,2-a]pyridine
Rendimiento 44.1%

Condiciones de reacción

Condiciones detalladas
See reaction.notes.procedure_details.

Tratamiento posterior

  1. 1
    OtroAfter the completion of the reaction
  2. 2
    Extracciónextracted three times with chloroform
  3. 3
    LavadoThe combined chloroform layer was washed with water
  4. 4
    Secadoa saturated sodium chloride solution, dried over anhydrous sodium sulfate
  5. 5
    Filtraciónfiltered
  6. 6
    Concentraciónconcentrated
  7. 7
    OtroThe resulting crude product was purified by flash silica gel column chromatography (elution solvent: chloroform)
  8. 8
    Otrofurther purified by recycle preparative HPLC (HPLC apparatus

Procedimiento

673 mg (corresponding to 2.0 mmol) of 2-(4′-hydroxyphenyl)-6-iodoimidazo[1,2-a]pyridine was dissolved in 25 mL of N,N-dimethylformamide, and 831 mg (corresponding to 6.0 mmol) of potassium carbonate was added thereto. 275 μL (corresponding to 3.0 mmol) of 1-bromo-3-fluoropropane was added to the resulting solution, and the solution was stirred for 24 hours at room temperature. After the completion of the reaction, the reaction solution was poured into water, and extracted three times with chloroform. The combined chloroform layer was washed with water and a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated. The resulting crude product was purified by flash silica gel column chromatography (elution solvent: chloroform), and further purified by recycle preparative HPLC (HPLC apparatus: LC-908 (under trade name; manufactured by Japan Analytical Industry Co., Ltd.); column: two of JAIGEL 2H (under trade name; manufactured by Japan Analytical Industry Co., Ltd.) connected together; mobile phase: chloroform), to obtain 349 mg (corresponding to 0.881 mmol) of 2-[4′-(3″-fluoropropoxy)phenyl]-6-iodoimidazo[1,2-a]pyridine (FIG. 5, Step 3).

Fuente

DOI: 10.6084/m9.figshare.5104873.v1Patente: US08277777B2uspto-grants-2012_10